Monoclonal Antibodies in CVD: What Does the Future Hold?

Slides:

Advertisements

Similar presentations

More than 90% compounds entering clinical trials fail to demonstrate safety and efficacy in human, despite evidence of safety and effectiveness in pre-

Advertisements

MOnoclonal antibodies and potential applications in migraine

Statin Myopathy (AHA/ACC/NHLBI)

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

PCSK9 Inhibitors Post-CVOTs

Statin Selection in the Elderly

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Learning Goals. Harnessing the Immune System: Mechanism of Action of Immunotherapies in B-Cell Malignancies.

Tailoring Statin Therapy in Women

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

Understanding Biologics

Patient 1: 53-Year-Old Man With CVD Risk Factors

Stepping Up Asthma Control for Effective Management

Select Topics in Cardiovascular Medicine

American Heart Association Scientific Sessions

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Understanding Statin Metabolism

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

An Update on PCSK9 Inhibitors

A Pharmacist's Guide to PCSK9 Inhibitors:

Evaluating LDL-C Recommendations

New Pathways in Lipid Care

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

Personalizing Statin Therapy in Patients With HIV

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

A Patient Journey Through Statin Intolerance

Improving Appropriate Access to PCSK9 Inhibitors

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

New LDL-C Lipid Targets

Radical New Concepts in Lipid Management

Exploring Statin Intolerance

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized.

Clinicians' Corner in Dyslipidemia

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

Practical Guidance on the Management of Pan-Negative NSCLC

Glucose Management and Statin Therapy

LDL Cholesterol.

What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy.

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Reducing Risk for CV Outcomes

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

A Family Affair.

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Pathogenesis of IBD, and the Role of Biologic Therapies

Tailoring Therapy in the Newly Diagnosed Patient With CLL

Glucose Management and Statin Therapy

Achieving Lipid Targets With PCSK9 Inhibition

Lipids, the Heart, and the Kidney

PCSK9 Inhibitors and Real-World Evidence

Presentation transcript:

Monoclonal Antibodies in CVD: What Does the Future Hold?

Goals

Monoclonal Antibodies: The Basics

Study of Monoclonal Antibodies in CVD

Gain-of-Function vs Loss-of-Function Mutations in PCSK9

The ARIC Study

Mechanism of Action

Phase 2 Trial of AMG 145 in Patients With Hypercholesterolemia

Phase 2 Trial of AMG 145: Selected Results

Phase 2 Trial of REGN727/SAR236553 in Patients With Hypercholesterolemia

Phase 2 Trial of REGN727/SAR236553: Selected Findings

Statin Intolerance

AEs in a Phase 2 Trial of AMG 145

AEs in a Phase 2 Trial of AMG 145 (cont)

AEs in a Phase 2 Trial of REGN727/ SAR236553

AEs in a Phase 2 Trial of REGN727/ SAR236553 (cont)

Potential Therapeutic Roles for PCSK9 Monoclonal Antibodies

Phase 3 Trials: ODYSSEY Outcomes

Phase 3 Trials: FOURIER Outcomes

The Effects on Lipoprotein(a)

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)